Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Pharnext planning U.S, EU submissions for Charcot-Marie-Tooth therapy on Phase III data

Jennie Walters
October 19, 2018 5:09 PM UTC

Pharnext S.A. (Euronext:ALPHA) plans to submit regulatory applications to FDA and EMA in 2H19 for PXT3003 to treat mild to moderate Charcot-Marie-Tooth 1A (CMT1A) disease after a high dose of the compound met the primary endpoint of improving patient disability in the Phase III PLEO-CMT trial in the indication.

In June, China's National Medical Products Administration (NMPA) granted Priority Review to an NDA for PXT3003 to treat CMT1A. The product is an oral solution of baclofen, naltrexone and sorbitol (see "Priority Review in China for Pharnext's PXT3003")...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Pharnext S.A.